A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
- Status
- RECRUITING
- Phase
- PHASE1
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
- Status
- RECRUITING
- Phase
- PHASE2
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Status
- RECRUITING
- Phase
- PHASE3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Status
- RECRUITING
- Phase
- PHASE3
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Status
- RECRUITING
- Phase
- PHASE3
The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
- Status
- RECRUITING
- Phase
- PHASE2
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2